Metformin Glucophage M90

Phase 3Small molecule

MMedical University of Vienna

Metformin Glucophage M90 is one of 9 small molecule programs targeting Metformin. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetforminActive, not recruiting

MetforminPhase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Metformin

#DrugCompanyPhaseTrials

Glucophage

Glucophage

20 3

Galvus

Novartis

Phase 3

6 4

Myoinositol

SSohag University

Phase 3

2 5

HDM1005 1

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

2 6

Metformin Glucophage M90

MMedical University of Vienna

Phase 3

1 7

Metformin Pill

FFudan University

Phase 2

1 8

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 9

Metformin /ml

RRanbaxy Laboratories Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metformin1 trial

Metformin Therapy in Non-diabetic AAA Patients

Active, not recruiting·MMedical University of Vienna·Phase 2/3·NCT03507413·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Metformin Glucophage M90. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metformin Glucophage M90 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metformin Glucophage M90. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Vienna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedical University of Vienna

Metformin Glucophage M90

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metformin1 trial

References

Drug Info

Quick Facts

Related News